---
title: "TRIUMPH-4: Obesity with Knee Osteoarthritis (First Phase 3 Readout)"
description: "The first Phase 3 trial of retatrutide to report results, evaluating weight loss and knee osteoarthritis pain reduction in adults with obesity and knee OA. Demonstrated 28.7% weight loss and 75% pain reduction at 12 mg/68 weeks."
url: https://retatrutide.med/clinical-trials/phase-3-triumph-4
date: 2025-12-15
lastUpdated: 2026-03-15
phase: "3"
trialName: "TRIUMPH-4"
status: "results-published"
source: retatrutide.med
sourceType: "clinical trial"
license: CC-BY-NC-SA-4.0
canonical: https://retatrutide.med/clinical-trials/phase-3-triumph-4
---
## Study Overview

TRIUMPH-4 was the first Phase 3 trial in the retatrutide development program to report results, announced by Eli Lilly in December 2025. The trial evaluated retatrutide in adults with obesity and knee osteoarthritis (OA), a population where excess body weight directly contributes to joint pain and disability. The results were historic: 28.7% mean weight loss at the 12 mg dose over 68 weeks — the largest weight reduction ever reported for any pharmaceutical agent in a Phase 3 clinical trial.

## Phase 3 Dose Escalation Protocol

The TRIUMPH Phase 3 program uses an updated escalation schedule compared to Phase 2, introducing a 6 mg intermediate step between 4 mg and 9 mg to improve gastrointestinal tolerability. All arms initiate at 2 mg with 4-week escalation intervals.

| Target Dose | Weeks 1–4 | Weeks 5–8 | Weeks 9–12 | Weeks 13–16 | Weeks 17+ |
|---|---|---|---|---|---|
| 4 mg | 2 mg | 4 mg | — | — | — |
| 9 mg | 2 mg | 4 mg | 6 mg | 9 mg | — |
| 12 mg | 2 mg | 4 mg | 6 mg | 9 mg | 12 mg |

A permanent dose reduction is permitted for management of gastrointestinal adverse events. The addition of the 6 mg step was not present in the Phase 2 escalation protocol.

Source: Giblin et al., *Diabetes Obes Metab*, January 2026.

## Key Results

### Weight Loss

TRIUMPH-4 demonstrated weight loss that exceeded even the impressive Phase 2 results:

| Treatment Arm | Mean Weight Loss (68 wk) |
|---|---|
| Placebo | -3.2% |
| Retatrutide 9 mg | -26.4% |
| Retatrutide 12 mg | -28.7% |

The 12 mg result represents a 4.5 percentage point improvement over the Phase 2 result of -24.2% at 48 weeks, driven by the longer treatment duration (68 vs. 48 weeks) and optimized dose escalation.

### Responder Analysis

| Threshold | 9 mg | 12 mg |
|---|---|---|
| At least 5% weight loss | 97% | 99% |
| At least 10% weight loss | 94% | 97% |
| At least 15% weight loss | 86% | 93% |
| At least 20% weight loss | 72% | 85% |
| At least 25% weight loss | 50% | 68% |

### Knee Osteoarthritis Outcomes

The co-primary endpoint of knee OA pain showed dramatic improvement:
- **WOMAC pain score**: 75% reduction from baseline at 12 mg
- **Physical function**: Significant improvement in stair climbing, walking, and daily activities
- **Stiffness**: Marked reduction in morning stiffness
- The magnitude of pain reduction exceeded expectations and may reflect both weight-related mechanical offloading and potential anti-inflammatory effects

## New Safety Signal: Dysesthesia

TRIUMPH-4 identified a new adverse event that was not prominent in Phase 2:

### Dysesthesia (Abnormal Sensation)

- **12 mg group**: 20.9% incidence
- **9 mg group**: 8.8% incidence
- **Placebo**: 0.7% incidence
- **Characterization**: Described as tingling, numbness, or altered sensation, primarily in extremities
- **Severity**: Predominantly mild to moderate; rarely led to treatment discontinuation
- **Onset**: Typically during dose escalation phase
- **Resolution**: Often resolved or diminished with continued treatment

This safety signal will require careful monitoring in subsequent TRIUMPH trials and will be a focus of regulatory review. The mechanism is not fully understood and may relate to glucagon receptor-mediated neuronal effects or rapid metabolic changes at higher doses.

### Other Adverse Events

The broader gastrointestinal safety profile was consistent with the incretin class:

| Adverse Event | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Nausea | 38.1% | 43.2% | 10.7% |
| Diarrhea | 34.7% | 33.1% | 13.4% |
| Vomiting | 20.4% | 20.9% | 0% |
| Constipation | 21.8% | 25.0% | 8.7% |
| Decreased appetite | 19.0% | 18.2% | 9.4% |
| Discontinuation due to AEs | 12.2% | 18.2% | 4.0% |

## Clinical Significance

### Exceeding Phase 2 Benchmarks

The TRIUMPH-4 results confirmed that Phase 3 weight loss exceeded Phase 2, a pattern not always seen in drug development. The longer treatment duration (68 weeks vs. 48 weeks) allowed the weight loss trajectory to progress further, though it may still not have fully plateaued.

### Obesity-Osteoarthritis Nexus

This trial validated retatrutide for a specific high-burden population:
- Approximately 240 million adults globally have symptomatic knee OA
- Obesity is the strongest modifiable risk factor for knee OA progression
- Current weight loss therapies have not been specifically tested in OA populations at this scale
- The 75% pain reduction may delay or prevent the need for knee replacement surgery

### Competitive Positioning

With 28.7% weight loss, retatrutide now has the highest Phase 3 weight loss data of any obesity drug in development or on the market, surpassing tirzepatide's ~22% in SURMOUNT-1.

## Publication

Topline results announced via Eli Lilly press release in December 2025. Full peer-reviewed publication is pending as of May 2026. Detailed data are expected to be presented at major medical meetings throughout 2026.